Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The decision is based on the phase 3 DESTINY-Breast11 trial
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
Subscribe To Our Newsletter & Stay Updated
